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addressing the regulation of functional
foods. 'Functional foods' is a concept that
everyone knows aboutbutforwhich there is
no official policy. The FDA must face the
issues raised bythese products to ensure that
functional foods become a public health
boon rather than the snake oil of the 21st
century.
Estrogen's a Natural in Herbal
Remedies
Patricia Eagon, an associate professor of
medicine at Pennsylvania's University of
Pittsburgh, decided to consult an herbalist
after she began to suspect that Premarin, the
prescription estrogen she was taking for
menopausal symptoms, was causing a rash
on her leg. The herbalist, whom she had
consulted before on other health matters,
gave her a mixture of several herbs to take
instead of Premarin. The concoction both
relieved Eagon's hot flashes and
piqued her curiosity about how the
herbal ingredientsworked.
Eagon decided to launch her own
experiment to find out. She conduct-
ed an estrogen-binding assay on 15
herbs commonly used in treating
menopause, including 3 from the
remedy she had taken herself. Herbs
that showed estrogenic activity in the
screening were then fed to rats that
had undergone ovariectomy. To test
the herbs' estrogenicity, Eagon
weighed the rats' uteri at the end of
the study and measured changes in
the concentration ofluteinizing hor-
mone in their blood (enlarged uterus
and decreased luteinizing hormone
concentration are both indicators of
estrogenic activity). The tests indicated an
estrogenic effect in four of the herbs-
chaste tree berry (Vitex agnus-castus), dong
quai (Angelica sinensis), American ginseng
(Panax quinquefolium), and black cohosh
(Cimicifuga racemosa). Eagon reported her
findings on 11 April 1999 at the annual
meeting of the American Association for
Cancer Research and is currently preparing
the results for publication.
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Herbal estrogens. A recent study by associate professor of medicine
Patricia Eagon suggests that some herbs may have powerful estrogenic
properties.
Eagon's findings have implications for
the fast-growing number ofpeople who are
embracing alternative medicine. According
to the U.S. Food and Drug Administration
(FDA), more than halfofall U.S. adults use
over-the-counter vitamins, dietary supple-
ments, or herbal remedies. Ann Fonfa,
founder ofthe New York City-based Annie
Appleseed Project to promote the study of
alternative cancer treatments, estimates
(based on national averages for the general
population) that 30% of menopausal
women treat themselves with medicinal
herbs, many because they believe such herbs
are safer and gentler than prescription
drugs. Yet they have no proofofthe herbs'
medicinal value and safety beyond the folk
wisdom ofherbalists; unlike pharmaceutical
manufacturers, manufacturers of herbal
remedies are not required by the FDA to
prove their products' safetyand efficacy.
Eagon's discovery ofestrogenicity in the
herbs she tested comes as no surprise to
some researchers. "While the specific find-
ings are new, there is well-known, well-
described estrogenic activity in plants," says
Daniel Sheehan, director of the Endocrine
Disruptor Knowledge Base Program of the
FDA's National Center for Toxicology
Research in Jefferson, Arkansas. He points
to the example ofsubterranean clover, a type
of clover that farmers have known for 50
years to cause reproductive failure in sheep.
While Eagon's research may help
explain why certain herbs may relieve hot
flashes and other menopausal symptoms, it
raises several more questions. Ofkey inter-
est is how these phytoestrogens react in the
body. "We really need to measure these
things inwomen," Eagon says.
Premarin has long been doctors' drug of
choice in treating menopause because it not
only relieves symptoms but also helps pre-
vent osteoporosis and heart disease.
However, the synthetic hormone also ele-
vates women's risk of breast and uterine
cancer, which scares many would-be users
away.
Because of the estrogenic activity she
observed in the herbs she studied, Eagon
feels compelled to warn women at high risk
of breast or uterine cancer against taking
them, as estrogen has been implicated in
some forms of cancer. Yet she admits she
doesn't know if the herbs promote cancer.
In fact, she says, "We may test these further
and find they inhibit cancer. It looks as if
soy has a positive effect in preventing breast
cancer. These herbs may also be able to pre-
vent it."
Eagon also doesn't know if estrogenic
herbs give women the same protection
against heart disease and osteoporosis that
synthetic estrogen does. "One question is,
how do estrogenic substances from plants
compare in activity with pharmaceutical
estrogens," says Fredi Kronenberg, director
ofthe Rosenthal Center for Complementary
and Alternative Medicine at Columbia
University College of Physicians and
Surgeons in New York City. "Do they have
a broadspectrum ofestrogenic activityor are
they more selective in action? We don't have
theansweryet.`
Some ofthose answers may come out of
Eagon's upcoming research. She first plans
to investigate whether the herbs inhibit or
promote breast cancer by feeding them to
rats with a genetic susceptibility to the dis-
ease. Eagon also plans to delve into the
herbs' effects on premenopausal
women. Younger women take
chaste tree berry and dong quai
for premenstrual syndrome,
amenorrhea, and infertility;
American ginseng is recommend-
ed for stomach upset, lack of
appetite, physical exhaustion,
and infection. Eagon would use
mice with intact ovaries to simu-
late the impact on pre-
menopausal women.
"People think [taking herbal
remedies] is like eating another
serving of broccoli," Eagon says.
"These things are not all benign.
The more we know about them,
the better offwe'll be."
Harvesting Monoclonal
Antibodies from Plants
When monoclonal antibodies were first
developed 20 years ago, they were hyped as
a magic bullet for curing cancer and other
diseases. However, killing cancer cells with
these immune proteins, which are artificially
produced and which neutralize one specific
antigen or foreign protein, was not as
straightforward as first assumed, and clinical
failures occurred. Moreover, the high costof
producing monoclonal antibodies by tradi-
tional cell fermentation methods limited
their applications. These setbacks have
forced scientists to look more realistically at
monoclonal antibodies.
Now, researchers at EPIcyte Pharma-
ceutical, based in San Diego, California,
hope to revitalize interest in monoclonal
antibodies with a new technology that pro-
duces large supplies ofthe proteins inexpen-
sively. Their new technology uses green
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plants to churn out large quantities of
"plantibodies." After undergoing some
genetic engineering, plant cells easily assem-
ble monoclonal antibodies. Plants are
expected to be able to make unlimited
quantities of plantibodies at prices that will
be 25-100 times less expensive than cell fer-
mentation methods.
The current standard cell fermentation
methods can produce just 5-10 kg of a
monoclonal antibody in a year. In compari-
son, EPIcyte plans to produce 10,000 kg of
key plantibodies per year. The current high
cost ofmonoclonal antibodies, which ranges
from $200 to $1,000 per gram, is predicted
to fall to $10-100 per gram or less as plants
produce tons ofplantibodies.
A large, cheap supply means that new
medical, consumer, and industrial applica-
tions for monoclonal antibodies could
become economically feasible. For instance,
plantibodies could target toxicants or pollu-
tants in large-scale water purification sys-
tems, theorizes biochemist Andrew Hiatt, a
developer of plantibodies who cofounded
EPlcyte in 1996 along with plant physiolo-
gist Mich Hein. Plantibodies that sequester
heavy metals or radioactive compounds
could become tools for bioremediation.
The first plantibodies were produced in
tobacco plants, but to meet commercial
demands, EPIcyte is developing corn that
produces monoclonal antibodies. Corn is
the most widely grown crop worldwide, and
its seed (kernel) naturally stores plantibodies
in a low-moisture environment that is
loaded with protective protease inhibitors.
Stored plantibodies can be purified as need-
ed by standard milling procedures. The
high-molecular-weight (300,000-400,000
daltons) plantibodies easily separate from
the low-molecular-weight (< 50,000 dal-
tons) corn proteins when solubilized.
The first clinical evidence ofplantibod-
ies' effectiveness appeared at Guy's Hospital
in London. A plantibody against
Streptococcus mutans, which produces lactic
acid and erodes tooth enamel, was produced
in tobacco plants. When brushed onto
human teeth for three weeks, the plantibody
prcvented tooth decay for up to four
months, as described in the May 1998 issue
ofNature Medicine. The plantibody "specif-
ically inhibits Streptococcus from binding to
tooth surfaces," says Hiatt.
EPIcyte holds exclusive license for plan-
tibody technology from The Scripps
Research Institute in LaJolla, California. In
alliance with ReProtect of Baltimore,
Maryland, EPIcyte is developing preclinical
topical gels that contain plantibodies for
herpesvirus types 1 and 2. In a study pub-
lished in the December 1998 issue of
Nature Biotechnology, scientists at ReProtect
applied an experimental plantibody to the
vaginas of mice, which prevented infection
with genital herpes. EPIcyte and ReProtect
scientists are planning a joint project to
make a more potent herpes plantibody to
protect newborn babies against transmission
of herpes from infected mothers during
delivery.
"The greatest potential for monoclonal
antibodies lies in prevention," says Kevin
Whaley, a reproductive biologist at The
Johns Hopkins University in Baltimore
who also works for ReProtect. From a pub-
lic health perspective, plantibodies are ide-
ally suited for preventing sexually transmit-
ted diseases as over-the-counter products.
More than 5 million people in the United
States are infected with sexually transmitted
diseases annually at an estimated cost of
$12 billion in medical treatment. Whaley
says, "[Monoclonal] antibodies are so
potent and so specific, they can be used in
novel ways," such as personal lubricants,
gels, or controlled-release devices for vagi-
nal insertion. To accommodate personal
preferences, several different user-friendly
formulations for plantibodies will be devel-
oped, says Whaley.
All Ears: Potential Help for
Noise-induced Hearing Loss
Two separate teams recently published find-
ings that may help prevent or reduce noise-
induced hearing loss, the most common
form of hearing loss. According to the
American Academy of Otolaryngology, an
estimated 16-24 million people in the
United States have some amount ofhearing
loss due to sensory hair cell loss. Hair-cell
loss can be caused by overexposure to loud
noise, ototoxic drugs (including some antibi-
otics and anticancer drugs), disease, genetic
factors, and simple aging. Experts generally
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agree that continuous noise levels over 80
decibels, or about the loudness ofa busy city
street, can be hazardous to hearing.
The cochlea, a bony, coiled, fluid-filled
structure of the inner ear, is lined with an
epithelial layercaHed the organ ofCorti. This
organ is lined with microscopic hair cells that
translate sound waves into nerve impulses
that are sent to the brain. Loud noises can
overstimulate andsubsequendy kill these hair
cells. Once the hair cells are damaged, the ear
can no longer transmit sound to the brain.
Although birds can regenerate damaged hair
cells, humans cannot; lost hair cells mean
permanent hearingloss.
Richard J. Salvi, a professor ofcommu-
nicative disorders and sciences at the
University ofBuffalo in NewYork, and col-
leagues Alfred Stracher and Abraham
Shulman, both of the State University of
New York Health Science Center in
Brooklyn, have discovered that a compound
called leupeptin may protect against noise-
induced hearing loss by preventing the loss
ofhair cells. The study was published in the
17 March 1999 issue ofNeuroReport.
The scientists infused the right cochleae
of several chinchillas with leupeptin for 14
days, while the left cochleae were left
untreated as a control. The chinchillas were
exposed to noise at either 100 or 105 deci-
bels for 48 hours. The scientists found that
the untreated cochleae lost massive amounts
of hair, ranging from nearly 100% in the
basal portion to about 15% in the upper-
most portions. Conversely, the treated
cochleae retained all but a few hairs.
Overall, leupeptin reduced the loss ofouter
hair cells-the cells that are first damaged
by noise-by an average of60%.
The studywas based on the premise that
exposure to loud noises causes an increased
production of calcium in nerve cells. This
starts a chain ofevents that eventually leads
to nerve degeneration. Leupeptin is one ofa
family ofpeptides that have been shown to
short-circuit this chain of events. It is not
clear, however, exactly how leupeptin works
to protect the hair cells.
In a companion study, the scientists
found that leupeptin didn't protect against
the ototoxic effects of the anticancer drug
carboplatin, possibly due to the mechanism
by which carboplatin causes hearing dam-
age. But Salvi is not discouraged; on the
contrary, he believes leupeptin or a similar
compound may yet be useful against the
effects of ototoxic drugs. "We hope com-
pounds like this will have some therapeutic
value, perhaps provide protection against
carboplatin or cisplatin [another anticancer
drug]" he says, adding that such com-
pounds could be used in tandem with oto-
toxic drugs.
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